Image Now with Proven Safety

Safe and effective in patients you care for every day1

Small spheres make a big difference

Adverse Reactions in Patients* (n=6856)1

Number (%) of Patients with Adverse Reactions Headache Nausea Dysgeusia Injection-site pain Feeling hot Chest discomfort Chest pain Dizziness Injection-site warmth
340 (5%) 65 (1%) 37 (0.5%) 29 (0.4%) 23 (0.3%) 18 (0.3%) 17 (0.2%) 12 (0.2%) 11 (0.2%) 11 (0.2%)
Feeling hot Chest discomfort Chest pain Dizziness Injection-site warmth
18 (0.3%) 17 (0.2%) 12 (0.2%) 11 (0.2%) 11 (0.2%)

*Occurring in at least 0.2% of patients.

LUMASON is an ultrasound contrast agent made up of SF6-filled microspheres.

Sulfur hexafluoride gas in LUMASON is inert and undergoes little or no biotransformation1

LUMASON microspheres are constructed of sulfur hexafluoride gas in a highly elastic shell4

  • 99% of LUMASON microspheres are ≤10 µm1
    • Upper size limit: 100% of LUMASON microspheres are ≤20 µm1
  • Designed to be stable and resist pressure changes4
  • Acoustic properties constant over the entire range of frequencies used in clinical settings5

LUMASON is known globally as SonoVue® which has been administered to millions of patients worldwide since its first approval in 2001.6

Sonographer

The individuals who appear are for illustrative purposes only.

INDICATIONS AND USAGE1

LUMASON is an ultrasound contrast agent indicated for use:

  • in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms
  • in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
  • in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS1

LUMASON is contraindicated in patients with:

  • history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON

IMPORTANT SAFETY INFORMATION1

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].

  • Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
  • Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)].1

Please see full Prescribing Information including boxed WARNING at http://www.braccoimaging.com/us-en/products-and-solutions/contrast-enhanced-ultrasound/lumason/prescribing-information

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike).

LUMASON is a registered trademark of Bracco Diagnostics Inc.

SonoVue is a registered trademark of Bracco Suisse S.A.

Bracco Diagnostics Inc.
259 Prospect Plains Road, Building H
Monroe Township, NJ 08831 USA
Phone: 609-514-2200
Toll Free: 1-877-272-2269 (U.S. only)
Fax: 609-514-2446

References: 1. LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use full Prescribing Information. Monroe Twp., NJ: Bracco Diagnostics Inc.; December 2016. 2. Papadopoulou F, Ntoulia A, Siomou E, Darge K. Contrast-enhanced voiding urosonography with intravesical administration of a second-generation ultrasound contrast agent for diagnosis of vesicoureteral reflux: prospective evaluation of contrast safety in 1,010 children. Pediatr Radiol. 2014;44(6):719-728. 3. Trillaud H, Bruel JM, Valette PJ, et al. Characterization of focal liver lesions with SonoVue-enhanced sonography: International multicenter-study in comparison to CT and MRI. World J Gastroenterol. 2009;15(30):3748-3756. 4. Schneider M. Characteristics of SonoVue™. Echocardiography. 1999;16(7, pt 2):743-746. 5. Schneider M, Arditi M, Barrau MB, et al. BR1: a new ultrasound contrast agent based on sulfur hexafluoride-filled microbubbles. Invest Radiol. 1995;30(8):451-457. 6. Data on file. Bracco Diagnostics Inc.